JPRN-UMIN000014302已完成2 期
Phase II study comparing combination therapy with carboplatin plus pemetrexed vs combination therapy with pemetrexed plus bevacizumab in chemo-naive elderly patients with advanced non-squamous non-small-cell lung cancer (HSR1402). - Carboplatin plus pemetrexed vs pemetrexed plus bevacizumab in chemo-naive elderly patients with advanced non-squamous non-small-cell lung cancer.
Hamamatsu Univ. School of Medicine0 个研究点目标入组 64 人开始时间: 2014年6月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 76years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. squamous histology 2. interstitial lung disease or pulmonary fibrosis 3. presence or history of hemoptysis 4. pleural effusion or cardiac effusion that needs to be treated 5. superior vena cava syndrome 6. uncontrolled and symptomatic brain metastasis except stable brain metastases after radiotherapy 7. uncontrolled diabetes, hypertension, liver damage, ischemic heart disease or myocardial infarction within three months. 8. severe infectious disease 9 pregnancy, lactation, or willing to get pregnant. 10. active malignancy of other organ. 11.history of severe hypersensitivity to drugs 12. bleeding diathesis or coagulopathy 13. symptomatic cerebrovascular disease, or history of brain attack 12 months prior to the study. 14. uncontrolled digestive ulcer or history of gastrointestinal perforation. 15. other severe comorbidities 16. judgement of discontinuation by attending physicians
研究者
相似试验
已完成
2 期
A phase II study of TAS-102 and RamucirumabJPRN-jRCT2080224529Taiho Pharmaceutical Co., Ltd.60
已完成
1 期
Phase I/II study on combination therapy consisting of a fixed dose-rate infusion of gemcitabine with oral fluorinated pyrimidine compound S-1 (FGS) in patients with gemcitabine-refractory advanced pancreatic cancerPatients with gemcitabine-refractory metastatic pancreatic cancerJPRN-C000000450ational Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division40
已完成
2 期
Multicenter Phase II study of combination therapy with S-1 plus Irinotecan plus Cetuximab (MetronomicIRIS/Cmab combination therapy) in patients with KRAS wild type unresectable colorectal cancer, who had previously received on fluoropyrimidine , oxaliplatin , irinotecan and bevacizumab. (KSCOG CR-06)Colorectal cancerJPRN-UMIN000012063Kurume University Medical Center30
尚未招募
不适用
Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancermetastatic breast cancerJPRN-UMIN000035869The University of Tokushima Graduate School, Depertment of Thoracic, Endocrine surgery and Oncology, Institute of Health Bioscience30
进行中（未招募）
不适用
Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor (ATX-study) - ATXEUCTR2006-006058-83-NLVU Medisch Centrum